| COVID-19 Vaccine |
1 |
0.95 |
| Vaccines |
0 |
0.66 |
| Immunization |
0 |
0.63 |
| Biologic Therapy |
0 |
0.61 |
| Clinical Guidelines |
0 |
0.52 |
| Herpes Zoster |
0 |
0.43 |
| Patient Safety |
0 |
0.43 |
| COVID-19 |
0 |
0.4 |
| Alabama |
0 |
0.36 |
| Monoclonal Antibody |
0 |
0.27 |
| Rheumatic Disease |
0 |
0.27 |
| Prophylaxis |
0 |
0.18 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.13 |
| Adverse Effects |
0 |
0.09 |
| Arthritis |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Intravenous |
0 |
0.09 |
| Jobs |
0 |
0.09 |
| Severe Acute Respiratory Syndrome |
0 |
0.09 |
| Targeted Cancer Therapy |
0 |
0.09 |
| Wasting |
0 |
0.09 |
| Osteoarthritis |
0 |
0.08 |
| Acute Respiratory Distress Syndrome |
0 |
0.05 |
| Influenza |
0 |
0.05 |
| Medical Life |
0 |
0.05 |
| Osteoporosis |
0 |
0.05 |